Chengning Zhang Ming Zeng Yifei Ge Kang Liu Changying Xing Huijuan Mao
10.3389/fimmu.2022.977377
Front Immunol
2022 Sep 12;13:977377.
acute kidney injury belimumab case report kidney replacement therapy severe active lupus nephritis
CC BY
https://pubmed.ncbi.nlm.nih.gov/36172377/
Lupus Erythematosus, Systemic / drug therapy Lupus Nephritis / chemically induced Lupus Nephritis / drug therapy
Lupus Erythematosus, Systemic / drug therapy Lupus Nephritis / chemically induced Lupus Nephritis / drug therapy Case Reports Review Research Support, Non-U.S. Gov't Antibodies, Monoclonal, Humanized / adverse effects Humans Immunosuppressive Agents / adverse effects Antibodies, Monoclonal, Humanized Immunosuppressive Agents belimumab
PMC9511409
36172377
Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review
2022